Detection of MGMT methylation status using a Lab-on-Chip compatible isothermal amplification method.

Area of Science:

• Biotechnology
• Molecular Diagnostics
• Oncology

Background:

• Rising cancer incidence demands efficient diagnostic tools.
• O-6-methylguanine-DNA methyltransferase (MGMT) is a key biomarker for glioblastoma (GBM) treatment response.
• Current methods for DNA methylation analysis can be time-consuming and expensive.

Purpose of the Study:

• To develop a novel, Lab-on-Chip (LOC) compatible method for detecting and quantifying MGMT DNA methylation.
• To establish a cost-effective, rapid, and precise diagnostic tool for personalized glioblastoma therapy.
• To demonstrate the clinical translatability of a new epigenetic biomarker detection platform.

Main Methods:

• Utilized a Lab-on-Chip compatible isothermal amplification method (LAMP) for sequence-specific detection of methylated MGMT DNA.
• Assessed the specificity and sensitivity of the LAMP method against established gold-standard techniques (MethyLight, JumpStart).
• Evaluated the method's performance using clinically relevant concentrations of bisulfite-converted DNA.

Main Results:

• Developed specific LAMP primer combinations targeting the methylated MGMT region.
• Demonstrated sensitivity capable of detecting clinically relevant DNA concentrations (0.2 - 20 ng/µL).
• Successfully showed DNA methylation detection on a Lab-on-Chip platform for the first time.

Conclusions:

• The novel LOC-LAMP method provides a specific and sensitive approach for MGMT DNA methylation detection.
• This platform offers a foundation for developing point-of-care epigenetic biomarker analysis.
• The technology has the potential to improve personalized glioblastoma treatment strategies.